Calidi Biotherapeutics reported a $3.6 million net loss for Q3 2026, improving from a $10.8 million loss in the same period last year. The company made significant progress with its lead cancer therapy candidate, CLD-401, showing strong anti-tumor effects in preclinical models and moving closer to clinical trials expected in late 2027. Calidi also reduced administrative costs by 39% and raised $1.2 million through a stock offering, while executing a restructuring plan to extend its cash runway. These steps aim to support ongoing development of their RedTail platform and in situ T-cell engager therapies targeting solid tumors.
Calidi Biotherapeutics' Q3 2026 financial results provide context for health-sector market activity. For readers following health stocks, here is Pluang's market snapshot as of Nov 14, 2026 04:11 WIB: out of 150 health-sector US stocks, 71 rose and 75 fell. Among notable movers, Alnylam Pharmaceuticals (ALNY) gained 5.80% to USD 165.74 with 100% buy orders and a typical hold time of 41 days, contrasting with Canopy Growth Corp (CGC) which dropped 5.79% to USD 0.57 over a similar hold period. Abeona Therapeutics (ABEO) rose 5.24% to USD 2.41 but saw a majority of sell orders at 67%, with a shorter hold time of 22 days.
ArrowMark Financial Corp. announced a monthly cash distribution of $0.15 per share for November 2026, payable on November 30 to shareholders of record as of November 23. This distribution reflects the company's ongoing commitment to provide current i...
Liberty Defense Holdings clarified details of its credit facility and term loan with Parabilis, originally announced in 2024. The company’s subsidiary received a $1.8 million term loan and a $2.5 million revolving credit facility, both secured by sub...
Stardust Power announced a $2.8 million net loss for Q3 2026, an improvement from $4.5 million last year, driven by lower administrative costs and warrant value changes. The company is progressing its lithium refinery project in Muskogee, Oklahoma, d...
byNordic Acquisition Corporation, a special purpose acquisition company, has extended its deadline to complete a business combination by one month, moving it from November 12, 2026, to December 12, 2026. This is the fourth of up to twelve possible on...
Texas Pacific Land Corporation reported a high Return on Invested Capital (ROIC) of 30.81%, significantly surpassing its Weighted Average Cost of Capital (WACC) of 7.73%. This strong performance results in the highest ROIC-to-WACC ratio of 3.98 among...
